BPP 2001/BPP 3001
Alternative Names: BPP-2001/BPP-3001Latest Information Update: 24 Jul 2025
At a glance
- Originator Beta Pharma
- Class Obesity therapies
- Mechanism of Action Glucagon-like peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity
Most Recent Events
- 24 Jul 2025 Early research in Obesity in USA (unspecified route), before July 2025 (Beta Pharma pipeline, July 2025)